Iteos Therapeutics Stock News

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Ansbert Gadicke sold 60,808 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The shares were sold at an average price of $36.29, for a total value of $2,206,722.32. The transaction was disclosed in a filing with the SEC, which can be accessed through []

Related Stocks: ITOS ,

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Ansbert Gadicke sold 60,808 shares of the firms stock in a transaction that occurred on Wednesday, November 24th. The shares were sold at an average price of $36.29, for a total transaction of $2,206,722.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []

Goldman Sachs Group Inc. lifted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 82.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 121,274 shares of the companys stock after purchasing an additional 54,723 shares during the quarter. Goldman []

iTeos Therapeutics, Inc. (NASDAQ:ITOS)s stock price shot up 4.4% during mid-day trading on Thursday . The stock traded as high as $35.30 and last traded at $35.30. 6,349 shares were traded during trading, a decline of 97% from the average session volume of 184,159 shares. The stock had previously closed at $33.82. Several brokerages have []

Cubist Systematic Strategies LLC bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,215 shares of the companys stock, valued at approximately $647,000. A number of other large []

iTeos Therapeutics (NASDAQ:ITOS) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Wednesday, Zacks.com reports. The brokerage currently has a $34.00 price objective on the stock. Zacks Investment Researchs target price would indicate a potential downside of 7.63% from the companys previous close. According to []

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock analysts at Wedbush raised their Q4 2021 earnings per share estimates for iTeos Therapeutics in a report released on Thursday, November 11th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $1.14 for the quarter, up from their previous forecast of ($0.42). Wedbush []

Related Stocks: ITOS , ALT , CRVS , LIFE , LPTX , TNGX , ASLN , BCTG ,

iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

iTeos Therapeutics (NASDAQ:ITOS) had its price target lowered by SVB Leerink from $55.00 to $54.00 in a research report report published on Friday, Price Targets.com reports. The brokerage currently has an outperform rating on the stock. A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of []

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Wedbush upped their Q4 2021 EPS estimates for iTeos Therapeutics in a report released on Thursday, November 11th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $1.14 per share for the quarter, up from their prior forecast of ($0.42). Wedbush also issued estimates for iTeos Therapeutics Q1 []

iTeos Therapeutics Inc. (ITOS) CEO Michel Detheux on Q3 2021 Results - Earnings Call Transcript

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th